1 – 7 of 7
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
- Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
- 2009
- Validation of the predictive value of tissue inhibitor of metalloproteinases-1 for the response to first-line chemotherapy in metastatic breast cancer.
- TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib
- 2006
- Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863)
- Reduced mortality for women with mammography-detected breast cancer in east Denmark and south Sweden
- 2003
- Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
- 2002
- Physical performance, toxicity, and quality of life as assessed by the physician and the patient